Slimming down Besides bolstering the pockets of big pharma, the economic potential of GLP-1s comes in its second- and third-order impacts
The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1 the first oral GLP-1 pill for weight loss that can be taken at any time of day, with no fasting, food, or water restrictions
These effects contribute to prolonged satiety and weight loss but also cause nausea, vomiting, and abdominal discomfort, particularly during dose escalation
1,2 Second Natures real-world data confirm that both medications achieve clinically significant weight loss for the vast majority of users: 95% with Mounjaro and 83% with Wegovy achieved at least 10% weight loss in our programme
The effects on your body mirror branded versions
You should write down any symptoms you have